{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T12:18:46Z","timestamp":1788437926968,"version":"build-2803163510"},"reference-count":81,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82300911"],"award-info":[{"award-number":["82300911"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["32201056"],"award-info":[{"award-number":["32201056"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["U22A20286, 82470854"],"award-info":[{"award-number":["U22A20286, 82470854"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"DOI":"10.1007\/s10238-026-02300-6","type":"journal-article","created":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T03:13:36Z","timestamp":1788405216000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Sodium-glucose cotransporter-2 inhibitors and gastrointestinal neoplasm risk in type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials"],"prefix":"10.1007","volume":"26","author":[{"given":"Yu-Fan","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Jie","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Yu","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Meng","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Man","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang-Yuan","family":"Teng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9534-6252","authenticated-orcid":false,"given":"Yong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,3]]},"reference":[{"issue":"12","key":"2300_CR1","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1097\/CM9.0000000000003536","volume":"138","author":"H Zhang","year":"2025","unstructured":"Zhang H, Jia Q, Song P, Li Y, Jiang L, Fu X, Li S. Incidence, prevalence, and burden of type 2 diabetes in China: Trend and projection from 1990 to 2050. Chin Med J. 2025;138(12):1447\u201355.","journal-title":"Chin Med J"},{"issue":"1","key":"2300_CR2","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1210\/endrev\/bnaa025","volume":"42","author":"W Horton","year":"2021","unstructured":"Horton W, Barrett E. Microvascular Dysfunction in Diabetes Mellitus and Cardiometabolic Disease. Endocr Rev. 2021;42(1):29\u201355.","journal-title":"Endocr Rev"},{"issue":"9","key":"2300_CR3","first-page":"e45835","volume":"15","author":"M Zakir","year":"2023","unstructured":"Zakir M, Ahuja N, Surksha M, Sachdev R, Kalariya Y, Nasir M, et al. Cardiovascular Complications of Diabetes: From Microvascular to Macrovascular Pathways. Cureus. 2023;15(9):e45835.","journal-title":"Cureus"},{"issue":"7","key":"2300_CR4","first-page":"991","volume":"23","author":"A Onitilo","year":"2012","unstructured":"Onitilo A, Engel J, Glurich I, Stankowski R, Williams G, Doi S. Diabetes and cancer II: role of diabetes medications and influence of shared risk factors. Cancer causes control: CCC. 2012;23(7):991\u20131008.","journal-title":"Cancer causes control: CCC"},{"key":"2300_CR5","doi-asserted-by":"publisher","first-page":"413782","DOI":"10.1155\/2012\/413782","volume":"2012","author":"M Hsieh","year":"2012","unstructured":"Hsieh M, Lee T, Cheng S, Tu S, Yen M, Tseng C. The influence of type 2 diabetes and glucose-lowering therapies on cancer risk in the Taiwanese. Experimental diabetes Res. 2012;2012:413782.","journal-title":"Experimental diabetes Res"},{"issue":"1","key":"2300_CR6","doi-asserted-by":"publisher","first-page":"8273","DOI":"10.1038\/s41598-017-07921-2","volume":"7","author":"M Zhao","year":"2017","unstructured":"Zhao M, Chen J, Yuan Y, Zou Z, Lai X, Rahmani D, et al. Dipeptidyl peptidase-4 inhibitors and cancer risk in patients with type 2 diabetes: a meta-analysis of randomized clinical trials. Sci Rep. 2017;7(1):8273.","journal-title":"Sci Rep"},{"key":"2300_CR7","doi-asserted-by":"publisher","first-page":"1532587","DOI":"10.3389\/fendo.2025.1532587","volume":"16","author":"Q Wu","year":"2025","unstructured":"Wu Q, Zeng Y, Liu Y, Teng F, Zhou T, Guo M, et al. A meta-analysis on the risk of esophageal cancer in type 2 diabetes patients treated with GLP-1 receptor agonists. Front Endocrinol (Lausanne). 2025;16:1532587.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"2300_CR8","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s12933-021-01213-w","volume":"20","author":"D Giugliano","year":"2021","unstructured":"Giugliano D, Longo M, Scappaticcio L, Caruso P, Esposito K. Sodium-glucose transporter-2 inhibitors for prevention and treatment of cardiorenal complications of type 2 diabetes. Cardiovasc Diabetol. 2021;20(1):17.","journal-title":"Cardiovasc Diabetol"},{"issue":"10","key":"2300_CR9","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.2215\/CJN.14901219","volume":"15","author":"A Levin","year":"2020","unstructured":"Levin A, Perkovic V, Wheeler D, Hantel S, George J, Eynatten VM, et al. Empagliflozin and Cardiovascular and Kidney Outcomes across KDIGO Risk Categories: Post Hoc Analysis of a Randomized, Double-Blind, Placebo-Controlled, Multinational Trial. Clin J Am Soc Nephrology: CJASN. 2020;15(10):1433\u201344.","journal-title":"Clin J Am Soc Nephrology: CJASN"},{"issue":"3","key":"2300_CR10","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s13300-015-0117-z","volume":"6","author":"G Fulcher","year":"2015","unstructured":"Fulcher G, Matthews D, Perkovic V, Zeeuw DD, Mahaffey K, Weiss R, et al. Efficacy and Safety of Canagliflozin Used in Conjunction with Sulfonylurea in Patients with Type 2 Diabetes Mellitus: A Randomized, Controlled Trial. Diabetes therapy: Res Treat Educ diabetes Relat disorders. 2015;6(3):289\u2013302.","journal-title":"Diabetes therapy: Res Treat Educ diabetes Relat disorders"},{"key":"2300_CR11","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.ejim.2023.01.021","volume":"110","author":"R Chan","year":"2023","unstructured":"Chan R, Chan R, Chou O, Tse G, Lee S. Lower risks of incident colorectal cancer in SGLT2i users compared to DPP4i users: A propensity score-matched study with competing risk analysis. Eur J Intern Med. 2023;110:125\u20137.","journal-title":"Eur J Intern Med"},{"key":"2300_CR12","doi-asserted-by":"crossref","unstructured":"Dutka M, Bobi\u0144ski R, Francuz T, Garczorz W, Zimmer K, Ilczak T et al. SGLT-2 Inhibitors in Cancer Treatment-Mechanisms of Action and Emerging New Perspectives. Cancers. 2022;14(23):5811.","DOI":"10.3390\/cancers14235811"},{"issue":"5","key":"2300_CR13","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1007\/s10120-024-01512-7","volume":"27","author":"O Chou","year":"2024","unstructured":"Chou O, Chauhan V, Chung C, Lu L, Lee T, Ng Z, et al. Comparative effectiveness of sodium-glucose cotransporter-2 inhibitors for new-onset gastric cancer and gastric diseases in patients with type 2 diabetes mellitus: a population-based cohort study. Gastric cancer: official J Int Gastric Cancer Association Japanese Gastric Cancer Association. 2024;27(5):947\u201370.","journal-title":"Gastric cancer: official J Int Gastric Cancer Association Japanese Gastric Cancer Association"},{"key":"2300_CR14","first-page":"n71","volume":"372","author":"M Page","year":"2021","unstructured":"Page M, McKenzie J, Bossuyt P, Boutron I, Hoffmann T, Mulrow C, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ (Clinical Res ed). 2021;372:n71.","journal-title":"BMJ (Clinical Res ed)"},{"key":"2300_CR15","doi-asserted-by":"publisher","first-page":"668368","DOI":"10.3389\/fpubh.2021.668368","volume":"9","author":"N Shi","year":"2021","unstructured":"Shi N, Shi Y, Xu J, Si Y, Yang T, Zhang M, et al. SGLT-2i and Risk of Malignancy in Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials. Front Public Health. 2021;9:668368.","journal-title":"Front Public Health"},{"issue":"Suppl 1","key":"2300_CR16","first-page":"S111","volume":"47","author":"6","year":"2024","unstructured":"6. Glycemic Goals and Hypoglycemia: Standards of Care in Diabetes-2024. Diabetes Care. 2024;47(Suppl 1):S111\u201325.","journal-title":"Diabetes Care"},{"key":"2300_CR17","unstructured":"World Obesity Atlas. 2025. https:\/\/www.worldobesity.org\/resources\/resource-library\/world-obesity-atlas-2025"},{"key":"2300_CR18","unstructured":"Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organization technical report series. 2000;894:i-xii, 1-253."},{"issue":"10","key":"2300_CR19","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1111\/j.1463-1326.2011.01434.x","volume":"13","author":"K Strojek","year":"2011","unstructured":"Strojek K, Yoon K, Hruba V, Elze M, Langkilde A, Parikh S. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial. Diabetes Obes Metab. 2011;13(10):928\u201338.","journal-title":"Diabetes Obes Metab"},{"key":"2300_CR20","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/1741-7015-11-43","volume":"11","author":"C Bailey","year":"2013","unstructured":"Bailey C, Gross J, Hennicken D, Iqbal N, Mansfield T, List J. Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial. BMC Med. 2013;11:43.","journal-title":"BMC Med"},{"issue":"5","key":"2300_CR21","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/S2213-8587(13)70208-0","volume":"2","author":"A Barnett","year":"2014","unstructured":"Barnett A, Mithal A, Manassie J, Jones R, Rattunde H, Woerle H, et al. Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial. lancet Diabetes Endocrinol. 2014;2(5):369\u201384.","journal-title":"lancet Diabetes Endocrinol"},{"issue":"11","key":"2300_CR22","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1517\/14656566.2014.935764","volume":"15","author":"N Inagaki","year":"2014","unstructured":"Inagaki N, Kondo K, Yoshinari T, Takahashi N, Susuta Y, Kuki H. Efficacy and safety of canagliflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled with diet and exercise: a 24-week, randomized, double-blind, placebo-controlled, Phase III study. Expert Opin Pharmacother. 2014;15(11):1501\u201315.","journal-title":"Expert Opin Pharmacother"},{"key":"2300_CR23","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/1475-2840-13-65","volume":"13","author":"K Kaku","year":"2014","unstructured":"Kaku K, Watada H, Iwamoto Y, Utsunomiya K, Terauchi Y, Tobe K, et al. Efficacy and safety of monotherapy with the novel sodium\/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: a combined Phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group comparative study. Cardiovasc Diabetol. 2014;13:65.","journal-title":"Cardiovasc Diabetol"},{"issue":"7","key":"2300_CR24","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1111\/jgs.12881","volume":"62","author":"L Leiter","year":"2014","unstructured":"Leiter L, Cefalu W, Bruin DT, Gause-Nilsson I, Sugg J, Parikh S. Dapagliflozin Added to Usual Care in Individuals with Type 2 Diabetes Mellitus with Preexisting Cardiovascular Disease: A 24\u2010Week, Multicenter, Randomized, Double\u2010Blind, Placebo\u2010Controlled Study with a 28\u2010Week Extension. J Am Geriatr Soc. 2014;62(7):1252\u201362.","journal-title":"J Am Geriatr Soc"},{"issue":"11","key":"2300_CR25","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1111\/dom.12327","volume":"16","author":"M Nauck","year":"2014","unstructured":"Nauck M, Prato DS, Dur\u00e1n-Garc\u00eda S, Rohwedder K, Langkilde A, Sugg J, et al. Durability of glycaemic efficacy over 2 years with dapagliflozin versus glipizide as add-on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin. Diabetes Obes Metab. 2014;16(11):1111\u201320.","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"2300_CR26","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.jcte.2014.04.001","volume":"1","author":"R Qiu","year":"2014","unstructured":"Qiu R, Capuano G, Meininger G. Efficacy and safety of twice-daily treatment with canagliflozin, a sodium glucose co-transporter 2 inhibitor, added on to metformin monotherapy in patients with type 2 diabetes mellitus. J Clin Translational Endocrinol. 2014;1(2):54\u201360.","journal-title":"J Clin Translational Endocrinol"},{"issue":"9","key":"2300_CR27","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/S2213-8587(14)70120-2","volume":"2","author":"M Ridderstr\u00e5le","year":"2014","unstructured":"Ridderstr\u00e5le M, Andersen K, Zeller C, Kim G, Woerle H, Broedl U. Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial. lancet Diabetes Endocrinol. 2014;2(9):691\u2013700.","journal-title":"lancet Diabetes Endocrinol"},{"issue":"7","key":"2300_CR28","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.2337\/dc13-3055","volume":"37","author":"J Rosenstock","year":"2014","unstructured":"Rosenstock J, Jelaska A, Frappin G, Salsali A, Kim G, Woerle H, et al. Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes. Diabetes Care. 2014;37(7):1815\u201323.","journal-title":"Diabetes Care"},{"issue":"2","key":"2300_CR29","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1111\/dom.12187","volume":"16","author":"J Wilding","year":"2014","unstructured":"Wilding J, Woo V, Rohwedder K, Sugg J, Parikh S. Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years. Diabetes Obes Metab. 2014;16(2):124\u201336.","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"2300_CR30","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1111\/dme.12624","volume":"32","author":"C Bailey","year":"2015","unstructured":"Bailey C, Morales Villegas E, Woo V, Tang W, Ptaszynska A, List J. Efficacy and safety of dapagliflozin monotherapy in people with Type 2 diabetes: a randomized double-blind placebo-controlled 102-week trial. Diabet medicine: J Br Diabet Association. 2015;32(4):531\u201341.","journal-title":"Diabet medicine: J Br Diabet Association"},{"key":"2300_CR31","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1186\/s12933-015-0314-0","volume":"14","author":"M Roden","year":"2015","unstructured":"Roden M, Merker L, Christiansen A, Roux F, Salsali A, Kim G, et al. Safety, tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-na\u00efve patients with type 2 diabetes: a double-blind extension of a Phase III randomized controlled trial. Cardiovasc Diabetol. 2015;14:154.","journal-title":"Cardiovasc Diabetol"},{"issue":"3","key":"2300_CR32","doi-asserted-by":"publisher","first-page":"376","DOI":"10.2337\/dc14-1142","volume":"38","author":"J Rosenstock","year":"2015","unstructured":"Rosenstock J, Hansen L, Zee P, Li Y, Cook W, Hirshberg B, et al. Dual add-on therapy in type 2 diabetes poorly controlled with metformin monotherapy: a randomized double-blind trial of saxagliptin plus dapagliflozin addition versus single addition of saxagliptin or dapagliflozin to metformin. Diabetes Care. 2015;38(3):376\u201383.","journal-title":"Diabetes Care"},{"issue":"10","key":"2300_CR33","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1111\/dom.12503","volume":"17","author":"J Rosenstock","year":"2015","unstructured":"Rosenstock J, Jelaska A, Zeller C, Kim G, Broedl U, Woerle H. Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78-week randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab. 2015;17(10):936\u201348.","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"2300_CR34","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.clinthera.2015.10.025","volume":"38","author":"M Haneda","year":"2016","unstructured":"Haneda M, Seino Y, Inagaki N, Kaku K, Sasaki T, Fukatsu A, et al. Influence of Renal Function on the 52-Week Efficacy and Safety of the Sodium Glucose Cotransporter 2 Inhibitor Luseogliflozin in Japanese Patients with Type 2 Diabetes Mellitus. Clin Ther. 2016;38(1):66\u2013e8820.","journal-title":"Clin Ther"},{"issue":"5","key":"2300_CR35","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1111\/dom.12888","volume":"19","author":"S Terra","year":"2017","unstructured":"Terra S, Focht K, Davies M, Frias J, Derosa G, Darekar A, et al. Phase III, efficacy and safety study of ertugliflozin monotherapy in people with type 2 diabetes mellitus inadequately controlled with diet and exercise alone. Diabetes Obes Metab. 2017;19(5):721\u20138.","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"2300_CR36","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1111\/dom.13194","volume":"20","author":"R Pratley","year":"2018","unstructured":"Pratley R, Eldor R, Raji A, Golm G, Huyck S, Qiu Y, et al. Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: The VERTIS FACTORIAL randomized trial. Diabetes Obes Metabolism. 2018;20(5):1111\u201320.","journal-title":"Diabetes Obes Metabolism"},{"issue":"3","key":"2300_CR37","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1111\/dom.13103","volume":"20","author":"J Rosenstock","year":"2018","unstructured":"Rosenstock J, Frias J, P\u00e1ll D, Charbonnel B, Pascu R, Saur D, et al. Effect of ertugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy (VERTIS MET). Diabetes Obes Metab. 2018;20(3):520\u20139.","journal-title":"Diabetes Obes Metab"},{"issue":"12","key":"2300_CR38","doi-asserted-by":"publisher","first-page":"2876","DOI":"10.1111\/dom.13473","volume":"20","author":"R Scott","year":"2018","unstructured":"Scott R, Morgan J, Zimmer Z, Lam R, O\u2019Neill E, Kaufman K, et al. A randomized clinical trial of the efficacy and safety of sitagliptin compared with dapagliflozin in patients with type 2 diabetes mellitus and mild renal insufficiency: The CompoSIT-R study. Diabetes Obes Metab. 2018;20(12):2876\u201384.","journal-title":"Diabetes Obes Metab"},{"issue":"7","key":"2300_CR39","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1111\/1753-0407.12634","volume":"10","author":"W Yang","year":"2018","unstructured":"Yang W, Ma J, Li Y, Li Y, Zhou Z, Kim J, et al. Dapagliflozin as add-on therapy in Asian patients with type 2 diabetes inadequately controlled on insulin with or without oral antihyperglycemic drugs: A randomized controlled trial. J diabetes. 2018;10(7):589\u201399.","journal-title":"J diabetes"},{"issue":"10","key":"2300_CR40","doi-asserted-by":"publisher","first-page":"2248","DOI":"10.1111\/dom.13801","volume":"21","author":"Y Halvorsen","year":"2019","unstructured":"Halvorsen Y, Lock J, Zhou W, Zhu F, Freeman MA. 24-week, randomized, double\u2010blind, active\u2010controlled clinical trial comparing bexagliflozin with sitagliptin as an adjunct to metformin for the treatment of type 2 diabetes in adults. Diabetes Obes Metabolism. 2019;21(10):2248\u201356.","journal-title":"Diabetes Obes Metabolism"},{"issue":"4","key":"2300_CR41","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1111\/dom.13928","volume":"22","author":"Y Halvorsen","year":"2020","unstructured":"Halvorsen Y, Walford G, Thurber T, Russell H, Massaro M, Freeman MA. 12-week, randomized, double-blind, placebo-controlled, four-arm dose-finding phase 2 study evaluating bexagliflozin as monotherapy for adults with type 2 diabetes. Diabetes Obes Metab. 2020;22(4):566\u201373.","journal-title":"Diabetes Obes Metab"},{"issue":"8","key":"2300_CR42","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1080\/03007995.2019.1583450","volume":"35","author":"P Hollander","year":"2019","unstructured":"Hollander P, Hill J, Johnson J, Jiang WZ, Golm G, Huyck S, et al. Results of VERTIS SU extension study: safety and efficacy of ertugliflozin treatment over 104 weeks compared to glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin. Curr Med Res Opin. 2019;35(8):1335\u201343.","journal-title":"Curr Med Res Opin"},{"issue":"6","key":"2300_CR43","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1111\/dom.13681","volume":"21","author":"L Ji","year":"2019","unstructured":"Ji L, Liu Y, Miao H, Xie Y, Yang M, Wang W, et al. Safety and efficacy of ertugliflozin in Asian patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: VERTIS Asia. Diabetes Obes Metab. 2019;21(6):1474\u201382.","journal-title":"Diabetes Obes Metab"},{"issue":"12","key":"2300_CR44","doi-asserted-by":"publisher","first-page":"2272","DOI":"10.2337\/dc19-0883","volume":"42","author":"H Rodbard","year":"2019","unstructured":"Rodbard H, Rosenstock J, Canani L, Deerochanawong C, Gumprecht J, Lindberg S, et al. Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial. Diabetes Care. 2019;42(12):2272\u201381.","journal-title":"Diabetes Care"},{"key":"2300_CR45","doi-asserted-by":"crossref","unstructured":"Fuchigami A, Shigiyama F, Kitazawa T, Okada Y, Ichijo T, Higa M et al. Efficacy of dapagliflozin versus sitagliptin on cardiometabolic risk factors in Japanese patients with type 2 diabetes: a prospective, randomized study (DIVERSITY-CVR). Cardiovasc Diabetol. 2020;19(1):1.","DOI":"10.1186\/s12933-019-0977-z"},{"issue":"10","key":"2300_CR46","doi-asserted-by":"publisher","first-page":"2528","DOI":"10.2337\/dc19-1350","volume":"43","author":"S Jabbour","year":"2020","unstructured":"Jabbour S, Fr\u00edas J, Ahmed A, Hardy E, Choi J, Sj\u00f6str\u00f6m C, et al. Efficacy and Safety Over 2 Years of Exenatide Plus Dapagliflozin in the DURATION-8 Study: A Multicenter, Double-Blind, Phase 3, Randomized Controlled Trial. Diabetes Care. 2020;43(10):2528\u201336.","journal-title":"Diabetes Care"},{"key":"2300_CR47","doi-asserted-by":"crossref","unstructured":"Katakami N, Mita T, Yoshii H, Shiraiwa T, Yasuda T, Okada Y et al. Tofogliflozin does not delay progression of carotid atherosclerosis in patients with type 2 diabetes: a prospective, randomized, open-label, parallel-group comparative study. Cardiovasc Diabetol. 2020;19(1):110.","DOI":"10.1186\/s12933-020-01079-4"},{"issue":"12","key":"2300_CR48","doi-asserted-by":"publisher","first-page":"2632","DOI":"10.1111\/dom.14513","volume":"23","author":"D Cherney","year":"2021","unstructured":"Cherney D, Ferrannini E, Umpierrez G, Peters A, Rosenstock J, Carroll A, et al. Efficacy and safety of sotagliflozin in patients with type 2 diabetes and severe renal impairment. Diabetes Obes Metabolism. 2021;23(12):2632\u201342.","journal-title":"Diabetes Obes Metabolism"},{"issue":"9","key":"2300_CR49","doi-asserted-by":"publisher","first-page":"2064","DOI":"10.2337\/dc21-2049","volume":"45","author":"Y Takeshita","year":"2022","unstructured":"Takeshita Y, Honda M, Harada K, Kita Y, Takata N, Tsujiguchi H, et al. Comparison of Tofogliflozin and Glimepiride Effects on Nonalcoholic Fatty Liver Disease in Participants With Type 2 Diabetes: A Randomized, 48-Week, Open-Label, Active-Controlled Trial. Diabetes Care. 2022;45(9):2064\u201375.","journal-title":"Diabetes Care"},{"issue":"12","key":"2300_CR50","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1111\/jdi.13888","volume":"13","author":"T Wada","year":"2022","unstructured":"Wada T, Mori-Anai K, Takahashi A, Matsui T, Inagaki M, Iida M, et al. Effect of canagliflozin on the decline of estimated glomerular filtration rate in chronic kidney disease patients with type 2 diabetes mellitus: A multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase III study in Japan. J Diabetes Investig. 2022;13(12):1981\u20139.","journal-title":"J Diabetes Investig"},{"issue":"6","key":"2300_CR51","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1111\/dom.15019","volume":"25","author":"D Cherney","year":"2023","unstructured":"Cherney D, Ferrannini E, Umpierrez G, Peters A, Rosenstock J, Powell D, et al. Efficacy and safety of sotagliflozin in patients with type 2 diabetes and stage 3 chronic kidney disease. Diabetes Obes Metab. 2023;25(6):1646\u201357.","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"2300_CR52","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2204233","volume":"388","author":"W Herrington","year":"2023","unstructured":"Herrington W, Staplin N, Wanner C, Green J, Hauske S, Emberson J, et al. Empagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2023;388(2):117\u201327.","journal-title":"N Engl J Med"},{"key":"2300_CR53","doi-asserted-by":"publisher","first-page":"1412553","DOI":"10.3389\/fendo.2024.1412553","volume":"15","author":"M Shimoda","year":"2024","unstructured":"Shimoda M, Katakura Y, Mashiko A, Iwamoto M, Nakanishi S, Anno T, et al. Comparison of protective effects of teneligliptin and luseogliflozin on pancreatic \u03b2-cell function: randomized, parallel-group, multicenter, open-label study (SECRETE-I study). Front Endocrinol (Lausanne). 2024;15:1412553.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"12","key":"2300_CR54","doi-asserted-by":"publisher","first-page":"2582","DOI":"10.1007\/s00125-013-3039-1","volume":"56","author":"F Lavalle-Gonz\u00e1lez","year":"2013","unstructured":"Lavalle-Gonz\u00e1lez F, Januszewicz A, Davidson J, Tong C, Qiu R, Canovatchel W, et al. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial. Diabetologia. 2013;56(12):2582\u201392.","journal-title":"Diabetologia"},{"issue":"3","key":"2300_CR55","doi-asserted-by":"publisher","first-page":"353","DOI":"10.2337\/dc15-1736","volume":"39","author":"J Rosenstock","year":"2016","unstructured":"Rosenstock J, Chuck L, Gonz\u00e1lez-Ortiz M, Merton K, Craig J, Capuano G, et al. Initial Combination Therapy With Canagliflozin Plus Metformin Versus Each Component as Monotherapy for Drug-Na\u00efve Type 2 Diabetes. Diabetes Care. 2016;39(3):353\u201362.","journal-title":"Diabetes Care"},{"issue":"6","key":"2300_CR56","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1111\/dom.12898","volume":"19","author":"T Kadowaki","year":"2017","unstructured":"Kadowaki T, Inagaki N, Kondo K, Nishimura K, Kaneko G, Maruyama N, et al. Efficacy and safety of canagliflozin as add-on therapy to teneligliptin in Japanese patients with type 2 diabetes mellitus: Results of a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab. 2017;19(6):874\u201382.","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"2300_CR57","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.clinthera.2013.11.002","volume":"36","author":"L Ji","year":"2014","unstructured":"Ji L, Ma J, Li H, Mansfield T, T\u2019Joen CL, Iqbal N, et al. Dapagliflozin as monotherapy in drug-naive Asian patients with type 2 diabetes mellitus: a randomized, blinded, prospective phase III study. Clin Ther. 2014;36(1):84\u2013e1009.","journal-title":"Clin Ther"},{"issue":"3","key":"2300_CR58","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1111\/dom.12829","volume":"19","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Matthews D, Mahaffey K, Fulcher G, Meininger G, et al. Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study-Renal (CANVAS-R): A randomized, placebo-controlled trial. Diabetes Obes Metab. 2017;19(3):387\u201393.","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"2300_CR59","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1159\/000484633","volume":"46","author":"M Jardine","year":"2017","unstructured":"Jardine M, Mahaffey K, Neal B, Agarwal R, Bakris G, Brenner B, et al. The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics. Am J Nephrol. 2017;46(6):462\u201372.","journal-title":"Am J Nephrol"},{"key":"2300_CR60","unstructured":"Lock JP. Bexagliflozin Efficacy and Safety Trial (BEST) 2019 [Available from: https:\/\/clinicaltrials.gov\/study\/NCT02558296?cond=NCT02558296&rank=1"},{"key":"2300_CR61","unstructured":"Pharmaceuticals L. Efficacy and Bone Safety of Sotagliflozin 400 and 200\u00a0mg Versus Placebo in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control (SOTA-BONE) 2020 [Available from: https:\/\/clinicaltrials.gov\/study\/NCT03386344?cond=NCT03386344&rank=1"},{"key":"2300_CR62","unstructured":"Lock JP. Safety and Efficacy of Bexagliflozin Compared to Glimepiride as Add-on Therapy to Metformin in Type 2 Diabetes Subjects 2019 [Available from: https:\/\/clinicaltrials.gov\/study\/NCT02769481?cond=NCT02769481&rank=1"},{"key":"2300_CR63","unstructured":"Pharmaceuticals L. Efficacy and Safety of Sotagliflozin Versus Placebo in Patients With Type 2 Diabetes Mellitus on Background of Metformin 2019 [Available from: https:\/\/clinicaltrials.gov\/study\/NCT02926950?cond=NCT02926950&rank=1"},{"key":"2300_CR64","unstructured":"Wason S. Efficacy and Safety of Sotagliflozin Versus Placebo in Participants With Type 2 Diabetes Mellitus on Background of Sulfonylurea Alone or With Metformin 2019 [Available from: https:\/\/clinicaltrials.gov\/study\/NCT03066830?cond=NCT03066830&rank=1"},{"key":"2300_CR65","unstructured":"Wason S. Efficacy and Safety of Sotagliflozin Versus Glimepiride and Placebo in Participants With Type 2 Diabetes Mellitus That Are Taking Metformin Monotherapy (SOTA-GLIM). 2019 [Available from: https:\/\/clinicaltrials.gov\/study\/NCT03332771?cond=NCT03332771&rank=1"},{"key":"2300_CR66","unstructured":"Wason S. Efficacy and Safety of Sotagliflozin Versus Placebo and Empagliflozin in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking a DPP4 Inhibitor Alone or With Metformin (SOTA-EMPA). 2019 [Available from: https:\/\/clinicaltrials.gov\/study\/NCT03351478?cond=NCT03351478&rank=1"},{"key":"2300_CR67","doi-asserted-by":"crossref","unstructured":"Pandey A, Alcaraz M Jr, Saggese P, Soto A, Gomez E et al. Exploring the Role of SGLT2 Inhibitors in Cancer: Mechanisms of Action and Therapeutic Opportunities. Cancers. 2025;17(3):466.","DOI":"10.3390\/cancers17030466"},{"issue":"2","key":"2300_CR68","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s00592-022-01981-1","volume":"60","author":"M Fakhrolmobasheri","year":"2023","unstructured":"Fakhrolmobasheri M, Abhari A, Manshaee B, Heidarpour M, Shafie D, Mohammadbeigi E, et al. Effect of sodium-glucose cotransporter 2 inhibitors on insulin resistance; a systematic review and meta-analysis. Acta Diabetol. 2023;60(2):191\u2013202.","journal-title":"Acta Diabetol"},{"issue":"1","key":"2300_CR69","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s00280-025-04788-3","volume":"95","author":"W Dong","year":"2025","unstructured":"Dong W, Wang Y, Fan S. Potential anticancer effects of sodium-glucose cotransporter protein 2 (SGLT2) inhibitors Canagliflozin and Dapagliflozin. Cancer Chemother Pharmacol. 2025;95(1):63.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"2300_CR70","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1038\/s42003-023-05289-w","volume":"6","author":"A Ali","year":"2023","unstructured":"Ali A, Mekhaeil B, Biziotis O, Tsakiridis E, Ahmadi E, Wu J, et al. The SGLT2 inhibitor canagliflozin suppresses growth and enhances prostate cancer response to radiotherapy. Commun biology. 2023;6(1):919.","journal-title":"Commun biology"},{"key":"2300_CR71","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1146\/annurev-pathmechdis-012418-012818","volume":"14","author":"S Ogino","year":"2019","unstructured":"Ogino S, Nowak J, Hamada T, Milner D Jr, Nishihara R. Insights into Pathogenic Interactions Among Environment, Host, and Tumor at the Crossroads of Molecular Pathology and Epidemiology. Annu Rev Pathol. 2019;14:83\u2013103.","journal-title":"Annu Rev Pathol"},{"issue":"3","key":"2300_CR72","doi-asserted-by":"publisher","first-page":"e3784","DOI":"10.1002\/dmrr.3784","volume":"40","author":"H Sung","year":"2024","unstructured":"Sung H, Hung C, Tung Y, Lin C, Tsai T, Huang K. Comparison between sodium-glucose cotransporter 2 inhibitors and dipeptidyl peptidase 4 inhibitors on the risk of incident cancer in patients with diabetes mellitus: A real-world evidence study. Diab\/Metab Res Rev. 2024;40(3):e3784.","journal-title":"Diab\/Metab Res Rev"},{"issue":"10","key":"2300_CR73","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.1007\/s00125-017-4370-8","volume":"60","author":"H Tang","year":"2017","unstructured":"Tang H, Dai Q, Shi W, Zhai S, Song Y, Han J. SGLT2 inhibitors and risk of cancer in type 2 diabetes: a systematic review and meta-analysis of randomised controlled trials. Diabetologia. 2017;60(10):1862\u201372.","journal-title":"Diabetologia"},{"issue":"16","key":"2300_CR74","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1016\/j.jacc.2024.01.040","volume":"83","author":"V Kittipibul","year":"2024","unstructured":"Kittipibul V, Cox Z, Chesdachai S, Fiuzat M, Lindenfeld J, Mentz R. Genitourinary Tract Infections in Patients Taking SGLT2 Inhibitors: JACC Review Topic of the Week. J Am Coll Cardiol. 2024;83(16):1568\u201378.","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"2300_CR75","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1161\/CIRCULATIONAHA.122.060823","volume":"146","author":"K Umanath","year":"2022","unstructured":"Umanath K, Testani J, Lewis J. Dip in eGFR: Stay the Course With SGLT-2 Inhibition. Circulation. 2022;146(6):463\u20135.","journal-title":"Circulation"},{"key":"2300_CR76","unstructured":"US Food and Drug Administration (FDA). FDA warns about rare occurrences of a serious infection of the genital area with SGLT2 inhibitors for diabetes. https:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm617360.htm. Accessed December 24, 2018. https:\/\/www"},{"key":"2300_CR77","doi-asserted-by":"crossref","unstructured":"Salvatore T, Galiero R, Caturano A, Rinaldi L, Martino DA, Albanese G et al. An Overview of the Cardiorenal Protective Mechanisms of SGLT2 Inhibitors. Int J Mol Sci. 2022;23(7):3651.","DOI":"10.3390\/ijms23073651"},{"key":"2300_CR78","doi-asserted-by":"publisher","unstructured":"Wang Y et al. Revisiting the association between sodium-glucose cotransporter-2 inhibitors and the risk of neoplasm in patients with type 2 diabetes: new insights from an updated systematic review and meta-analysis of randomized controlled trials. Expert review of clinical pharmacology vol. 18,3 (2025): 165\u201373. https:\/\/doi.org\/10.1080\/17512433.2024.2439970","DOI":"10.1080\/17512433.2024.2439970"},{"issue":"1","key":"2300_CR79","doi-asserted-by":"publisher","first-page":"2400797","DOI":"10.1080\/20565623.2024.2400797","volume":"10","author":"MI Obaid","year":"2024","unstructured":"Obaid MI, et al. Relationship between SGLT2 inhibitor use and specific cancer types: a systematic review and meta-analysis. Future Sci OA vol. 2024;10(1):2400797. https:\/\/doi.org\/10.1080\/20565623.2024.2400797.","journal-title":"Future Sci OA vol"},{"issue":"5","key":"2300_CR80","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1007\/s11096-025-01924-0","volume":"47","author":"B Xu","year":"2025","unstructured":"Xu B, Kang B, Li S, Chen J, Zhou J. Association between sodium-glucose cotransporter 2 inhibitors and cancer: a systematic review and meta-analysis of randomized active-controlled trials. Int J Clin Pharm. 2025;47(5):1121\u201331.","journal-title":"Int J Clin Pharm"},{"issue":"3","key":"2300_CR81","doi-asserted-by":"publisher","first-page":"e00145","DOI":"10.1002\/edm2.145","volume":"3","author":"R Pelletier","year":"2020","unstructured":"Pelletier R, Ng K, Alkabbani W, Labib Y, Mourad N, Gamble J. The association of sodium-glucose cotransporter 2 inhibitors with cancer: An overview of quantitative systematic reviews. Endocrinol diabetes metabolism. 2020;3(3):e00145.","journal-title":"Endocrinol diabetes metabolism"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-026-02300-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-026-02300-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-026-02300-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T12:02:44Z","timestamp":1788436964000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-026-02300-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,3]]},"references-count":81,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2300"],"URL":"https:\/\/doi.org\/10.1007\/s10238-026-02300-6","relation":{},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,3]]},"assertion":[{"value":"31 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests.","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All the authors have provided their consent for publication of the manuscript.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"319"}}